Parallel Advisors, LLC Bei Gene, Ltd. Transaction History

Parallel Advisors, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 28, 2022	SELL	$146.52 - $269.56 $31,355 - $57,685	-214 Closed	0 $0
Q4 2021 Jan 20, 2022	BUY	$248.56 - $389.34 $1,739 - $2,725	7 Added 3.38%	214 $58,000
Q3 2021 Nov 02, 2021	BUY	$249.6 - $403.14 $5,491 - $8,869	22 Added 11.89%	207 $75,000
Q2 2021 Aug 06, 2021	BUY	$292.75 - $367.01 $9,953 - $12,478	34 Added 22.52%	185 $63,000
Q1 2021 Apr 23, 2021	BUY	$260.64 - $382.12 $4,170 - $6,113	16 Added 11.85%	151 $53,000
Q4 2020 Feb 02, 2021	BUY	$221.31 - $316.61 $7,745 - $11,081	35 Added 35.0%	135 $35,000
Q3 2020 Oct 27, 2020	BUY	$189.18 - $286.44 $4,918 - $7,447	26 Added 35.14%	100 $29,000
Q2 2020 Jul 16, 2020	SELL	$123.9 - $195.41 $13,876 - $21,885	-112 Reduced 60.22%	74 $13,000
Q1 2020 Apr 27, 2020	BUY	$121.84 - $173.19 $1,949 - $2,771	16 Added 9.41%	186 $22,000
Q3 2019 Nov 01, 2019	BUY	$120.61 - $148.29 $1,085 - $1,334	9 Added 5.59%	170 $21,000
Q2 2019 Aug 05, 2019	BUY	$113.99 - $146.86 $18,352 - $23,644	161 New	161 $20,000

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.6B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Parallel Advisors, LLC with notifications on news.